Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.

ABSTRACT: BACKGROUND:The role of aspirin in primary prevention of cardiovascular disease (CVD) remains unclear. We aimed to investigate the benefit-risk ratio of aspirin for primary prevention of CVD with a particular focus on subgroups. METHODS:Randomized controlled trials comparing the effects of aspirin for primary prevention of CVD versus control and including at least 1000 patients were eligible for this meta-analysis. The primary efficacy outcome was all-cause mortality. Secondary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), myocardial infarction, ischemic stroke, and net clinical benefit. The primary safety outcome was major bleeding. Subgroup analyses involving sex, concomitant statin treatment, diabetes, and smoking were performed. RESULTS:Thirteen

SUBMITTER: Gelbenegger G 

PROVIDER: S-EPMC6827248 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature